Literature DB >> 22995327

Differential expression of extracellular matrix-related genes in rare variants of meningioma.

Mi Jung Kwon1, Chang Ohk Sung, So Young Kang, In-Gu Do, Yeon-Lim Suh.   

Abstract

Secretory, clear cell, and rhabdoid meningiomas are rare variants of meningiomas characterized by unique histologies and behaviors. Extracellular matrix proteins provide a morphologic structure and influence the biologic behavior of tumors. However, the effects of extracellular matrix proteins on morphologies and biologic behaviors of secretory meningioma, clear cell meningioma, and rhabdoid meningioma have not been established. We evaluated the expression of matrix metalloproteinase 2, matrix metalloproteinase 9, galectin-3, fibronectin, and collagen IV in a series of those rare variants of meningioma and verified their clinicopathologic significance. A total 51 cases included 12 secretory meningiomas, 9 clear cell meningiomas, and 30 rhabdoid meningiomas. Extracellular matrix proteins showed different expression patterns according to the histologic subtypes, and messenger RNA levels were well correlated with immunoexpressions. Secretory meningiomas showed high expressions of fibronectin and galectin-3. Clear cell meningiomas showed high expression of matrix metalloproteinase 2, matrix metalloproteinase 9, and collagen IV. Rhabdoid meningiomas showed high expressions of matrix metalloproteinase 9, galectin-3, and fibronectin. Clinically, high expression of matrix metalloproteinase 9 was associated with tumor recurrence (P < .001) and local invasion at the time of diagnosis (P = .018) among the extracellular matrix-related proteins, and was also associated with shorter recurrence-free survival (P = .025) in the patients with rhabdoid meningioma. In conclusion, the differential expressions of extracellular matrix-related genes according to the histologic subtypes appear to be involved in biologic behavior and clinical outcome, and high matrix metalloproteinase 9 expression is associated with recurrences in rhabdoid meningiomas.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995327     DOI: 10.1016/j.humpath.2012.05.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  ATF3 and extracellular matrix-related genes associated with the process of chronic obstructive pulmonary.

Authors:  Jia Ye; Li Wen; De-Ling Liu; Guo-xiang Lai
Journal:  Lung       Date:  2014-08-14       Impact factor: 2.584

2.  Integrin-based meningioma cell migration is promoted by photon but not by carbon-ion irradiation.

Authors:  Florian Simon; Jan-Oliver Dittmar; Stephan Brons; Lena Orschiedt; Steffi Urbschat; Klaus-Josef Weber; Jürgen Debus; Stephanie E Combs; Stefan Rieken
Journal:  Strahlenther Onkol       Date:  2014-12-02       Impact factor: 3.621

Review 3.  Meningioma Tumor Microenvironment.

Authors:  Sajad Sahab-Negah; Ali Gorji
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature.

Authors:  Rachael A Vaubel; Selby G Chen; David R Raleigh; Michael J Link; Michael R Chicoine; Igor Barani; Sarah M Jenkins; Patrice Abell Aleff; Fausto J Rodriguez; Peter C Burger; Sonika Dahiya; Arie Perry; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2015-12-07       Impact factor: 3.685

5.  Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.

Authors:  Joanna Reszec; Adam Hermanowicz; Robert Rutkowski; Grzegorz Turek; Zenon Mariak; Lech Chyczewski
Journal:  Biomed Res Int       Date:  2015-03-03       Impact factor: 3.411

Review 6.  Molecular Mechanism and Approach in Progression of Meningioma.

Authors:  Zhiwei Shao; Lihong Liu; Yanghao Zheng; Sheng Tu; Yuanbo Pan; Sheng Yan; Qichun Wei; Anwen Shao; Jianmin Zhang
Journal:  Front Oncol       Date:  2020-09-11       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.